http://repository.usmf.md:80/xmlui/handle/20.500.12710/24163 Sun, 26 Apr 2026 13:40:15 GMT 2026-04-26T13:40:15Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/24197 Revista de Științe ale Sănătății din Moldova = Moldovan Journal of Health Sciences. 2022, Vol. 28(2) Revista de Științe ale Sănătății din Moldova (Moldovan Journal of Health Sciences) a fost lansată în octombrie 2014. Aceasta este editată în limbile română și engleză, conform standardelor și ghidurilor internaționale actuale în domeniul științelor medicale, și are o apariție trimestrială. Revista este înregistrată în Instrumentul Bibliometric Național IBN/IDSI (nr.1 din 16.11.2015), iar din 21 decembrie 2017, prin Hotărârea Consiliului Suprem pentru Știință și Dezvoltare Tehnologică nr. 169, a fost inclusă în lista revistelor științifice de Tip B. Revista este înregistrată în 2 baze de date internaționale. Sat, 01 Jan 2022 00:00:00 GMT http://repository.usmf.md:80/xmlui/handle/20.500.12710/24197 2022-01-01T00:00:00Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/24196 COVID-19 infection and liver damage in children. Clinical case study. Liubarscaia, Svetlana; Raba, Tatiana; Ciobanu, Lucia; Chiosea, Lilia; Tihai, Olga Abstract Introduction. COVID-19 is currently considered a systemic disease affecting the immune system, primarily, lungs, heart, central nervous system, kidneys, intestines, liver and spleen. Impaired liver function and the presence of biochemical changes in liver can be found in approximately 14-53% of adults infected with SARS-CoV-2. Impaired liver function in patients infected with COVID-19 may occur due to a direct effect of the virus on hepatocytes, as well as being secondary to factors such as a systemic inflammatory response of the infected host, the onset of hypoxia (associated with lung damage), multiple organ failure, or due to abusive treatment using overlapping and hepatotoxic drugs. The purpose of this article is to describe a clinical case study regarding the clinical and paraclinical manifestations of liver damage in a 12-year-old child infected with SARSCoV-2, hospitalized at the Municipal Children’s Clinical Hospital „Valentin Ignatenco”, Republic of Moldova. Material and methods. The epidemiological, clinical and paraclinical data were used to highlight this study, followed by the conclusions of multidisciplinary specialists, retrieved from the inpatient medical records of the 12-yearold child with moderate COVID-19 infection, who was admitted for emergency treatment. Results. A 12-year-old patient F. was admitted to the „Covid-19” subunit, complaining of severe general malaise, fever up to 39°C, cough, rhinorrhea. The objective clinical examination revealed hepatomegaly and lack of splenomegaly. Laboratory findings determined leukocytosis 15.88 x109 /l, neutrophilia 72.2%, lymphopenia 26.1%, increased ESR (Erythrocyte Sedimentation rate) – 20 mm/h, increased CRP (C-reactive protein) >12.0 mg/l, increased ALT (alanine aminotransferase) by 16 (50.9-487-764 U/l) values compared to the normal reference and a 3-fold increase in AST (aspartate aminotransferase) that is higher than the normal range (55.8 - 113 - 181 U/l), an increased fibrinogen - 5.3 g/l, increased ferritin - 2834 pmol/l and D-dimer levels - 762 ng/ml. Hepatomegaly was detected on abdominal ultrasound. Covid-19 infection was confirmed by a rapid test of nasopharyngeal exudate for SARS-CoV-2 antigens. Conclusions. Patients with the novel coronavirus (COVID-19) show varying degrees of liver dysfunction, especially those with increased levels of AST and ALT. A question arises within the clinical practice, as whether the liver damage occurred due to direct viral hepatotoxicity or due to the drugs used in COVID-19 treatment. Sat, 01 Jan 2022 00:00:00 GMT http://repository.usmf.md:80/xmlui/handle/20.500.12710/24196 2022-01-01T00:00:00Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/24195 Evaluation of topical remedies in the treatment of acne available in the Republic of Moldova Virlan, Adrian; Guranda, Diana; Ciobanu, Cristina Summary Introduction. A lot of research and studies are currently being carried out in the field of elaboration and optimization of topical pharmaceutical forms used in the treatment of various types of acne. Acne vulgaris is a disease with a complex etiopathogenesis with potential negative psychosocial effects on the quality of life of patients, and its prevention is based on the successful management of risk factors. There are currently many topical and systemic treatment options available, so the choice of therapy depends on the form and severity of the condition. The advantage of topical pharmaceutical forms is the ability to target early stages of acne lesions. Material and methods. Statistical, systemic, informational and sociological analysis were used as methods of analysis. Documentation with the State Drug Nomenclature and Classification, evaluation of topical prescription for acne treatment, dispensed in the Vasile Procopisin University Pharmaceutical Center (UPhC), the study of active pharmaceutical ingredients (API) and technological characteristics of topical pharmaceutical forms. Results. Topical treatment for acne should be based on its type and severity. The basic therapy for the treatment of mild acne refers to external applications, due to their action to prevent lesions. Treatment should be maintained over time to prevent recurrence. For domestic patients are accessible drugs with keratolytic, bacteriostatic and anti-inflammatory properties for topical treatments as benzoyl peroxide, salicylic acid, sulfur, azelaic acid, zinc oxide and antibiotic. The analysis of the use of anti-acne medications, in treating mild to moderate acne, by the age group, identified that for adolescents treatment is being focused on combating the causative agent of sebum production using salicylic acid in 32.5% cases and with age increase, the aim is to suppress inflammatory processes requiring retinoids, and in case of absence, can be substituted by benzoyl peroxide. Conclusions. The therapeutic approach in clinical practice must be done individually, considering the severity and shape of acne lesions. Sat, 01 Jan 2022 00:00:00 GMT http://repository.usmf.md:80/xmlui/handle/20.500.12710/24195 2022-01-01T00:00:00Z http://repository.usmf.md:80/xmlui/handle/20.500.12710/24194 Novel biomarkers in systemic sclerosis Agachi, Svetlana; Groppa, Liliana; Rotaru, Larisa; Deseatnicova, Elena; Chișlari, Lia; Russu, Eugeniu Abstract Introduction. Due to the heterogeneous nature of systemic sclerosis, it is difficult to predict disease progression and complications. Despite the discovery of novel autoantibodies associated with systemic sclerosis (SSc), there is an unmet need for biomarkers for diagnosis, disease progression, and response to treatment. Materials and methods. An analytical, qualitative study was performed with a narrative review of literature in the form of a synthesis article. Relevant primary sources published in 2020-2022 were identified and selected, using data extraction and analysis. Results. Anti-citrullinated protein/peptide antibody could be useful in identifying patients with a more prominent joint disease. Of most interest, the anti-carbamylated protein antibodies (anti-CarP) could be a relevant biomarker related to fibrotic skin and lung disease. Positive anti-RNA (Ribonucleic acid) polymerase III antibody and antinuclear antibodies (ANA) negativity were significantly associated with GAVE (gastral antral vascular ectasia). Autoantibodies against telomeres may help identify systemic sclerosis with lung disease. Osteopontin links myeloid activation and disease progression in systemic sclerosis. CTRP (C1q tumor necrosis factor-related proteins) 9 protein levels may be biomarker of lung disease severity. CD (cluster differentiation) 21-low B cells are linked to vascular damage. L-tyrosine, L-tryptophan, and 1-methyl-adenosine distinguished healthy controls from SSc patients. L-leucine, L-isoleucine, xanthosine, and adenosine monophosphate differentiated between progressing and stable SSc-ILD. CECs (circulating endothelial cells) are a direct indicator of systemic vascular damage. Levels of the protein, galectin-3, are associated with heart involvement in people with systemic sclerosis. Low levels of the galectin-10 protein (Gal-10) in scleroderma patients associate with inflammation and vascular changes in the lungs, leading to pulmonary arterial hypertension (PAH). High levels of the CD146 protein may be a potential biomarker in identifying people with systemic sclerosis. Blood levels of the protein endocan increased in scleroderma patients who are at risk for pulmonary arterial hypertension. FLCs (free light chain) could be employed as useful potential biomarker of early diagnosis and to follow disease activity. Conclusions. Novel discovered biomarkers could predict disease development, activity, and severity of diverse organ involvement, predict risk of complications of systemic sclerosis. Sat, 01 Jan 2022 00:00:00 GMT http://repository.usmf.md:80/xmlui/handle/20.500.12710/24194 2022-01-01T00:00:00Z